EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Comparing criteria for objective cognitive staging in preclinical Alzheimer's disease

Kelsey K Amon, Chao Huang, Holly H Fleischmann, Stephen Correia, Andrew M Kiselica

Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · 2026-10 · 18 (4)

DOI: 10.1002/dad2.70527 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, online erschienen am 09.11.2026. Verfasst von Kelsey K Amon und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychology University of Kentucky Lexington Kentucky USA. Die Arbeit nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Alzheimer's Association, GHR Foundation, Foundation for Neurologic Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION Individuals with preclinical Alzheimer's disease may develop objective subtle cognitive decline (OSCD) as they transition between the cognitively unimpaired and mild cognitive impairment stages. Selection of individuals with OSCD into clinical trials may provide enrichment for participants likely to benefit from treatment. We examined how choice of operational criteria for OSCD impacted clinical staging. METHODS We analyzed data from 6154 older adults in the Anti‐Amyloid Treatment in Asymptomatic Alzheimer's Disease clinical trial to evaluate differences in clinical categorization rates by operational approach, as well as interactions with sex, race, and ethnicity. RESULTS: Multinomial generalized estimating equation models yielded significant differences in clinical categorization rates: Interview‐based methods led to the lowest proportion of individuals categorized with OSCD, cognitive screeners yielded the highest proportion, and multi‐test neuropsychological methods provided a balance. These main effects were moderated by significant interactions with sex and race/ethnicity. DISCUSSION Choice of OSCD criteria will have significant impacts on trial sample makeup.

Schlagwörter

Stichwörter der Autor:innen

Alzheimer's diseaseclinical stagingclinical trial screeningobjective subtle cognitive declinepreclinical cognitive declinetransitional cognitive decline

Autor:innen und Institutionen

  • Department of Psychology University of Kentucky Lexington Kentucky USA.
  • Department of Epidemiology & Biostatistics College of Public Health University of Georgia Athens Georgia USA.
  • Department of Psychology Franklin College of Arts and Sciences University of Georgia Athens Georgia USA.
  • Institute of Gerontology University of Georgia Athens Georgia USA.
  • Department of Health Promotion and Behavior University of Georgia Athens Georgia USA.
  • Department of Health Policy and Management University of Georgia Athens Georgia USA.

Förderung

  • Alzheimer's Association
  • GHR Foundation
  • Foundation for Neurologic Diseases
  • Eli Lilly and Company

Zitieren

APA

Amon, K. K., Huang, C., Fleischmann, H. H., Correia, S., & Kiselica, A. M. (2026). Comparing criteria for objective cognitive staging in preclinical Alzheimer's disease. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, 18(4). https://doi.org/10.1002/dad2.70527

Vancouver

Amon KK, Huang C, Fleischmann HH, Correia S, Kiselica AM. Comparing criteria for objective cognitive staging in preclinical Alzheimer's disease. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring. 2026;18(4). doi:10.1002/dad2.70527

BibTeX
@article{Amon2026,
  author = {Amon, Kelsey K and Huang, Chao and Fleischmann, Holly H and Correia, Stephen and Kiselica, Andrew M},
  title = {Comparing criteria for objective cognitive staging in preclinical Alzheimer's disease},
  journal = {Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring},
  year = {2026},
  volume = {18},
  number = {4},
  doi = {10.1002/dad2.70527}
}
Kostenlos starten →